TY - JOUR
T1 - HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis
AU - Meza-Romero, Roberto
AU - Benedek, Gil
AU - Yu, Xiaolin
AU - Mooney, Jeffery L.
AU - Dahan, Rony
AU - Duvshani, Nerri
AU - Bucala, Richard
AU - Offner, Halina
AU - Reiter, Yoram
AU - Burrows, Gregory G.
AU - Vandenbark, Arthur A.
PY - 2014/5/1
Y1 - 2014/5/1
N2 - CD74, the cell-surface form of the MHC class II invariant chain, is a key inflammatory factor that is involved in various immunemediated diseases as part of the macrophage migration inhibitory factor (MIF) binding complex. However, little is known about the natural regulators of CD74 in this context. In order to study the role of the HLA-DR molecule in regulating CD74, we used the HLADRa1 domain, which was shown to bind to and downregulate CD74 on CD11b+ monocytes. We found that DRa1 directly inhibited binding of MIF to CD74 and blocked its downstream inflammatory effects in the spinal cord of mice with experimental autoimmune encephalomyelitis (EAE). Potency of the DRa1 domain could be destroyed by trypsin digestion but enhanced by addition of a peptide extension (myelin oligodendrocyte glycoprotein [MOG]-35-55 peptide) that provided secondary structure not present in DRa1. These data suggest a conformationally sensitive determinant on DRa1-MOG that is responsible for optimal binding to CD74 and antagonism of MIF effects, resulting in reduced axonal damage and reversal of ongoing clinical and histological signs of EAE. These results demonstrate natural antagonist activity of DRa1 for MIF that was strongly potentiated by the MOG peptide extension, resulting in a novel therapeutic, DRa1-MOG-35-55, that within the limitations of the EAE model may have the potential to treat autoimmune diseases such as multiple sclerosis. The Journal of Immunology, 2014, 192: 4164-4173.
AB - CD74, the cell-surface form of the MHC class II invariant chain, is a key inflammatory factor that is involved in various immunemediated diseases as part of the macrophage migration inhibitory factor (MIF) binding complex. However, little is known about the natural regulators of CD74 in this context. In order to study the role of the HLA-DR molecule in regulating CD74, we used the HLADRa1 domain, which was shown to bind to and downregulate CD74 on CD11b+ monocytes. We found that DRa1 directly inhibited binding of MIF to CD74 and blocked its downstream inflammatory effects in the spinal cord of mice with experimental autoimmune encephalomyelitis (EAE). Potency of the DRa1 domain could be destroyed by trypsin digestion but enhanced by addition of a peptide extension (myelin oligodendrocyte glycoprotein [MOG]-35-55 peptide) that provided secondary structure not present in DRa1. These data suggest a conformationally sensitive determinant on DRa1-MOG that is responsible for optimal binding to CD74 and antagonism of MIF effects, resulting in reduced axonal damage and reversal of ongoing clinical and histological signs of EAE. These results demonstrate natural antagonist activity of DRa1 for MIF that was strongly potentiated by the MOG peptide extension, resulting in a novel therapeutic, DRa1-MOG-35-55, that within the limitations of the EAE model may have the potential to treat autoimmune diseases such as multiple sclerosis. The Journal of Immunology, 2014, 192: 4164-4173.
UR - http://www.scopus.com/inward/record.url?scp=84899521602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899521602&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1303118
DO - 10.4049/jimmunol.1303118
M3 - Article
C2 - 24683185
AN - SCOPUS:84899521602
SN - 0022-1767
VL - 192
SP - 4164
EP - 4173
JO - Journal of Immunology
JF - Journal of Immunology
IS - 9
ER -